|1.||Iwata, Masao: 2 articles (01/2014 - 03/2004)|
|2.||Kashyap, Manoj K: 1 article (07/2015)|
|3.||Villa, Reymundo: 1 article (07/2015)|
|4.||La Clair, James J: 1 article (07/2015)|
|5.||Rassenti, Laura Z: 1 article (07/2015)|
|6.||Kumar, Deepak: 1 article (07/2015)|
|7.||Benner, Chris: 1 article (07/2015)|
|8.||Kipps, Thomas J: 1 article (07/2015)|
|9.||Sasik, Roman: 1 article (07/2015)|
|10.||Burkart, Michael D: 1 article (07/2015)|
|1.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
07/01/2015 - "Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B."
07/01/2015 - "We report studies using FD-895 and pladienolide-B in primary leukemia cells derived from patients with chronic lymphocytic leukemia and leukemia-lymphoma cell lines. "
01/24/2014 - "Pladienolide B (PB) is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the spliceosome. "
01/24/2014 - "Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs."
01/01/2014 - "When 18 SCID mice xenografted with primary cultured cells from three patients were administered the pladienolide B derivative intraperitoneally, all tumors completely disappeared within 2 weeks after treatment. "
03/01/2004 - "In the most sensitive model, using BSY-1 xenografts, tumors were completely regressed by administration of pladienolide B. "
03/01/2004 - "Pladienolide B extensively inhibited tumor growth in xenograft models. "
|5.||Stomach Neoplasms (Stomach Cancer)
01/01/2014 - "In conclusion, pladienolide B was very active against gastric cancer via a mechanism involving splicing impairment and apoptosis induction."
01/01/2014 - "The mean IC50 value of pladienolide B derivative against primary cultured cells from 12 gastric cancer patients was 4.9 ± 4.7 nM, indicative of high antitumor activity. "
01/01/2014 - "The effect of pladienolide B and its derivative on six gastric cancer cell lines was investigated using a MTT assay and the mean IC50 values determined to be 1.6 ± 1.2 (range, 0.6-4.0) and 1.2 ± 1.1 (range, 0.4-3.4) nM, respectively, suggesting strong antitumor activity against gastric cancer. "
01/01/2014 - "The antitumor activity of pladienolide B, a novel splicing inhibitor, against gastric cancer is totally unknown and no predictive biomarker of pladienolide B efficacy has been reported. "
01/01/2014 - "High antitumor activity of pladienolide B and its derivative in gastric cancer."
|3.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|5.||Cell Cycle Proteins
|6.||Biological Markers (Surrogate Marker)
|7.||Messenger RNA (mRNA)
|8.||RNA (Ribonucleic Acid)
|9.||DNA (Deoxyribonucleic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)